p21 Antibody / CDKN1A

The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.

The concentration stated for each application is a general starting point. Variations in protocols, secondaries and substrates may require the p21 antibody to be titered up or down for optimal performance.

1. Staining of formalin-fixed tissues requires
2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.

This antibody recognizes a 21kDa protein, identified as the p21 or p21WAF1 tumor suppressor protein. This antibody is highly specific and shows no cross-reaction with other closely related mitotic inhibitors. p21 is a specific inhibitor of cdk's and a tumor suppressor involved in the pathogenesis of a variety of malignancies. The expression of this gene acts as an inhibitor of the cell cycle during G1 phase and is tightly controlled by the tumor suppressor protein p53. p21 expression is induced by the wild type, but not mutant, p53. Normal cells generally display a rather intense nuclear expression. Loss of p21 expression has been reported in many carcinomas (gastric carcinoma, non-small cell lung carcinoma, thyroid carcinoma).

Purified

Prediluted in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide; *For IHC use only*

1026

Human recombinant protein was used as the immunogen for this p21 antibody.

This p21 antibody is available for research use only.

Nuclear

Protein G affinity chromatography